CLVS - Clovis Oncology, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
16.58
-0.71 (-4.11%)
At close: 4:00PM EDT

16.58 0.00 (0.00%)
After hours: 4:09PM EDT

Stock chart is not supported by your current browser
Previous Close17.29
Open17.04
Bid16.55 x 1800
Ask16.56 x 800
Day's Range16.41 - 17.14
52 Week Range11.50 - 50.00
Volume979,685
Avg. Volume1,613,367
Market Cap878.82M
Beta (3Y Monthly)1.88
PE Ratio (TTM)N/A
EPS (TTM)-7.16
Earnings DateJul 30, 2019 - Aug 5, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est30.20
Trade prices are not sourced from all markets
  • Business Wire3 days ago

    Clovis Oncology Presents Patient-Centered Outcomes Data from Phase 3 ARIEL3 Study for Rubraca®▼ in Advanced Ovarian Cancer

    Quality-adjusted progression free survival and quality-adjusted time without cancer related symptoms or toxicity demonstrate the benefit of Rubraca maintenance t

  • Business Wire7 days ago

    Clovis Oncology Announces Presentations at 2019 ASCO Annual Meeting

    Accepted abstracts highlight additional data from phase 3 ARIEL3 clinical trial, genomic data from phase 2 TRITON2 clinical trial, and the designs of other ongoing rucaparib trials

  • Thomson Reuters StreetEvents8 days ago

    Edited Transcript of CLVS earnings conference call or presentation 7-May-19 12:30pm GMT

    Q1 2019 Clovis Oncology Inc Earnings Call

  • Clovis (CLVS) Q1 Earnings Top Estimates, Rubraca Sales Strong
    Zacks15 days ago

    Clovis (CLVS) Q1 Earnings Top Estimates, Rubraca Sales Strong

    Clovis (CLVS) reports encouraging first-quarter 2019 results. Rubraca maintains market share during the quarter.

  • Clovis Oncology (CLVS) Q1 2019 Earnings Call Transcript
    Motley Fool15 days ago

    Clovis Oncology (CLVS) Q1 2019 Earnings Call Transcript

    CLVS earnings call for the period ending March 31, 2019.

  • Clovis Oncology (CLVS) Reports Q1 Loss, Tops Revenue Estimates
    Zacks16 days ago

    Clovis Oncology (CLVS) Reports Q1 Loss, Tops Revenue Estimates

    Clovis (CLVS) delivered earnings and revenue surprises of 9.44% and 4.53%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press16 days ago

    Clovis: 1Q Earnings Snapshot

    The Boulder, Colorado-based company said it had a loss of $1.63 per share. The results beat Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research was for ...

  • Markit16 days ago

    See what the IHS Markit Score report has to say about Clovis Oncology Inc.

    Clovis Oncology Inc NASDAQ/NGS:CLVSView full report here! Summary * Bearish sentiment is moderate and declining * Economic output in this company's sector is expanding Bearish sentimentShort interest | NeutralShort interest is moderately high for CLVS with between 10 and 15% of shares outstanding currently on loan. However, this was an improvement in sentiment as investors who seek to profit from falling equity prices reduced their short positions on April 12. Money flowETF/Index ownership | PositiveETF activity is positive. Over the last month, ETFs holding CLVS are favorable, with net inflows of $3.04 billion. Additionally, the rate of inflows is increasing. Economic sentimentPMI by IHS Markit | PositiveAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, and is accelerating. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • Business Wire16 days ago

    Clovis Oncology Announces First Quarter 2019 Operating Results

    BOULDER, Colo.-- -- $33.1M in Rubraca ® global sales for the first quarter of 2018 Updated data on 52 patients with BRCA-mutant mCRPC provided to FDA; RECIST response rate highly consistent with that shown at ESMO 2018 Targeting late 2019 for supplemental NDA filing for BRCA-mutant advanced prostate cancer; data update expected at Fall 2019 medical meeting Clovis-sponsored combination studies of lucitanib ...

  • Soleno Therapeutics (SLNO) to Post Q1 Earnings: What's Up?
    Zacks17 days ago

    Soleno Therapeutics (SLNO) to Post Q1 Earnings: What's Up?

    During Soleno Therapeutics' (SLNO) Q1 conference call, investor focus will be on its progress with the ongoing study on DCCR tablets, developed for the treatment of Prader-Willi syndrome.

  • What's in the Cards for Perrigo (PRGO) This Earnings Season?
    Zacks17 days ago

    What's in the Cards for Perrigo (PRGO) This Earnings Season?

    Perrigo (PRGO) is focused on Consumer Healthcare Americas segment. Let's see if it aids the company's results in the soon-to-be reported quarter.

  • Cronos (CRON) to Report Q1 Earnings: What's in the Cards?
    Zacks17 days ago

    Cronos (CRON) to Report Q1 Earnings: What's in the Cards?

    Investors will focus on Cronos' (CRON) regular top and bottom-line numbers along with its pipeline progress when the company reports Q1 results.

  • Business Wire17 days ago

    Clovis Oncology to Present at the Bank of America Merrill Lynch Healthcare Conference 2019

    Clovis Oncology, Inc. (CLVS) today announced that Patrick J. Mahaffy, Chief Executive Officer and President, will present at the Bank of America Merrill Lynch Healthcare Conference 2019 on Tuesday, May 14, 2019 at 2:20 PM Pacific Time. Clovis Oncology, Inc. is a biopharmaceutical company focused on acquiring, developing and commercializing innovative anti-cancer agents in the U.S., Europe and additional international markets. Clovis Oncology targets development programs at specific subsets of cancer populations, and simultaneously develops, with partners, for those indications that require them, diagnostic tools intended to direct a compound in development to the population that is most likely to benefit from its use.

  • Here’s What Hedge Funds Think About About Clovis Oncology Inc (CLVS)
    Insider Monkey20 days ago

    Here’s What Hedge Funds Think About About Clovis Oncology Inc (CLVS)

    "October lived up to its scary reputation—the S&P 500 falling in the month by the largest amount in the last 40 years, the only worse Octobers being '08 and the Crash of '87\. For perspective, there have been only 5 occasions in those 40 years when the S&P 500 declined by greater than 20% from […]

  • Business Wire21 days ago

    Clovis Oncology Enters into Non-Dilutive Clinical Trial Financing with TPG Sixth Street Partners for up to $175 Million

    Clovis Oncology, Inc. (CLVS) today announced that it has entered into an agreement for up to $175 million in non-dilutive clinical trial financing with certain affiliates of TPG Sixth Street Partners to reimburse Clovis’ costs and expenses related to the ATHENA clinical trial. ATHENA is Clovis Oncology’s largest clinical trial, with a planned target enrollment of 1000 patients across more than 270 sites in at least 25 countries.

  • Clovis Oncology (CLVS) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
    Zacks23 days ago

    Clovis Oncology (CLVS) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

    Clovis (CLVS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • What Are Analysts Saying About The Future Of Clovis Oncology, Inc.'s (NASDAQ:CLVS)?
    Simply Wall St.28 days ago

    What Are Analysts Saying About The Future Of Clovis Oncology, Inc.'s (NASDAQ:CLVS)?

    The latest earnings announcement Clovis Oncology, Inc. (NASDAQ:CLVS) released in December 2018 showed company earnings became less negative compared to the previous year's level as a result of recent...

  • Business Wire29 days ago

    Clovis Oncology to Announce First Quarter 2019 Financial Results and Host Webcast Conference Call on May 7

    Clovis Oncology, Inc. will announce its first quarter 2019 financial results on Tuesday, May 7, 2019, before the open of the U.S. financial markets. Clovis’ senior management will host a conference call and live audio webcast at 8:30 a.m.

  • Clovis Focuses on Rubraca Label Expansion, Competition Stiff
    Zackslast month

    Clovis Focuses on Rubraca Label Expansion, Competition Stiff

    Although sales of Clovis' (CLVS) Rubraca improved in the fourth quarter of 2018, the drug may face significant competition going forward. Clovis is also evaluating Rubrca for other cancer indications.

  • Company News For Apr 16, 2019
    Zackslast month

    Company News For Apr 16, 2019

    Companies in the news are: ADSW, WM, APHA, CLVS and LYFT

  • InvestorPlacelast month

    Clovis Oncology News: CLVS Stock Sinks on Trial for Cancer Treatment

    In the latest Clovis Oncology (NASDAQ:CLVS), the company's stock took a major hit as one of its trials for a drug designed to treat cancer has been halted suddenly.The Boulder, Colorado-brand said on Friday that it would no longer continue the phase two trial of its rucaparib treatment that was designed to help patients with bladder cancer, a report close to the matter said. The company decided to stop the trial after a recommendation from an independent monitoring committee was sent its way, the Dow Jones said.Clovis Oncology added that the committee recommendation was not the result of a "safety profile" of the treatment, Dow Jones added. CLVS stock was down roughly 14% after the bell on Friday following the company's announcement.InvestorPlace - Stock Market News, Stock Advice & Trading TipsShares then fell about 11.9% on Monday, sending the price of its stock to now be at $20.69 per share. At the beginning of the year, the stock was trading at $19.39 per share, which means that it has still managed to increase by about 6.7% throughout 2019.Clovis Oncology was founded about 10 years ago in the aforementioned mountain town, where it is currently headquartered. It is listed in the NASDAQ Biotechnology Index and it has several products in its product pipeline.These include rociletinib, which is designed to treat non-small cell lung cancer, with a phase III trial of the drug completed in April 2016. Rucaparib is designed to treat ovarian cancer, while lucitanib treats advanced solid tumors. More From InvestorPlace * 7 Marijuana Companies: Which Pot Stocks Should You Buy? * 7 AI Stocks to Watch with Strong Long-Term Narratives * 10 Dow Jones Stocks Holding the Blue Chip Index Back Compare Brokers The post Clovis Oncology News: CLVS Stock Sinks on Trial for Cancer Treatment appeared first on InvestorPlace.

  • Here's Why Clovis Oncology Stock Dropped as Much as 13% Today
    Motley Foollast month

    Here's Why Clovis Oncology Stock Dropped as Much as 13% Today

    The company decided to discontinue an important clinical trial.

  • Analysts, Options Traders Swarm Sinking CLVS Stock
    Schaeffer's Investment Researchlast month

    Analysts, Options Traders Swarm Sinking CLVS Stock

    The drugmaker halted a mid-stage trial in bladder cancer patients

  • Clovis Stalls Mid-Stage Rubraca Study for Bladder Cancer
    Zackslast month

    Clovis Stalls Mid-Stage Rubraca Study for Bladder Cancer

    Clovis Oncology (CLVS) halts mid-stage bladder cancer study evaluating Rubraca monotherapy. It is unlikely to provide meaningful clinical benefit as reviewed by an independent data monitoring committee.